Efficacy of Therapy With the Spironolactone Pills Compared to Minoxidil Lotion in Female Pattern Hair Loss

Condition(s) targeted: Female Pattern Hair Loss

Intervention: Spironolactone (Drug); Minoxidil (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: University of British Columbia

Official(s) and/or principal investigator(s):
Jerry Shapiro, MD, Principal Investigator, Affiliation: University of British Columbia

Overall contact:
Andreas Finner, Phone: 604 875 4747, Email: andreas.finner@vch.ca

This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.

Official title: Efficacy of Therapy With the Anti-Androgen Spironolactone Compared to Topical Minoxidil in Female Pattern Hair Loss

Study design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study

Primary outcome: hair density

Secondary outcome:

percentage of subjects who experience side effects

subject assessment of treatment effect

Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Subjects must be premenopausal women older than 18 with female pattern hair loss.

Exclusion Criteria:

- Androgen excess

- Other scalp or hair disorders

- Contraindications to spironolactone treatment, especially pregnancy, electrolyte

imbalances, history of breast cancer, or intake of interfering drugs

- Contraindications to minoxidil treatment, especially patients who are allergic to this

treatment or have a history of low blood pressure or irregular heart beats

Andreas Finner, Phone: 604 875 4747, Email: andreas.finner@vch.ca

UBC Division of Dermatology, Hair Research and Treatment Centre, Vancouver, British Columbia V6G 1Y6, Canada; Recruiting
Andreas Finner, Phone: 604 875 4747
Jerry Shapiro, MD, Principal Investigator

Starting date: September 2005
Ending date: December 2010
Last updated: September 22, 2008